Synopsis
Synopsis
0
EU WC
0
VMF
0
FDA Orange Book
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. D-glc
2. D-glucopyranose
3. D-glucopyranoside
4. Glc
5. Glucopyranose
6. Glucopyranoside
7. Glucose
8. 2280-44-6
9. Grape Sugar
10. D-glcp
11. (3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
12. Traubenzucker
13. Glucose Solution
14. Dextrose Solution
15. Chebi:4167
16. Corn Sugar
17. Glucopyranose, D-
18. 54-17-1
19. (3r,4s,5s,6r)-6-(hydroxymethyl)tetrahydro-2h-pyran-2,3,4,5-tetraol
20. Dsstox_cid_2910
21. Rel-(3r,4s,5s,6r)-6-(hydroxymethyl)tetrahydro-2h-pyran-2,3,4,5-tetraol
22. Glucodin
23. Goldsugar
24. Meritose
25. Vadex
26. Clintose L
27. Cpc Hydrate
28. Roferose St
29. A-d-glucose
30. Clearsweet 95
31. A-d-glucopyranose
32. Staleydex 95m
33. Staleydex 111
34. (+)-glucose
35. Cerelose 2001
36. Tabfine 097(hs)
37. 2h-pyran-2,3,4,5-tetraol
38. D-glucopyranose, Anhydrous
39. Glc-ring
40. Cartose Cerelose
41. D-glucose-ring
42. Glucose Injection
43. Glucose 40
44. Staleydex 130
45. Einecs 218-914-5
46. Glc-oh
47. Meritose 200
48. Nchembio867-comp4
49. Dextrose, Unspecified
50. Glucose (jp17)
51. Starbld0000491
52. 6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetraol
53. Anhydrous Glucose ,(s)
54. Glucose, Unspecified Form
55. Dextrose, Unspecified Form
56. Purified Glucose (jp17)
57. Epitope Id:142342
58. D-(+)-dextrose
59. Dsstox_rid_76784
60. Dsstox_rid_82925
61. Dsstox_gsid_22910
62. Dsstox_gsid_48729
63. Gtpl4536
64. Chembl1222250
65. Bdbm34103
66. Dtxsid501015215
67. Dtxsid901015217
68. Tox21_113165
69. Tox21_200145
70. Akos025147374
71. Nsc 287045
72. Cas-50-99-7
73. Ncgc00166293-01
74. Ncgc00257699-01
75. Bs-48662
76. Cas-58367-01-4
77. G0048
78. (3r,4s,5s,6r)-6-(hydroxymethyl)tetrahydro-
79. C00031
80. D00009
81. F71542
82. Q37525
83. Q23905964
84. N_full/o_full_10000000000000_gs_656
85. D-glucose (closed Ring Structure, Complete Stereochemistry)
86. Wurcs=2.0/1,1,0/[a2122h-1x_1-5]/1/
Molecular Weight | 180.16 g/mol |
---|---|
Molecular Formula | C6H12O6 |
XLogP3 | -2.6 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 1 |
Exact Mass | 180.06338810 g/mol |
Monoisotopic Mass | 180.06338810 g/mol |
Topological Polar Surface Area | 110 Ų |
Heavy Atom Count | 12 |
Formal Charge | 0 |
Complexity | 151 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Glucose pharmaceutical formulations (oral tablets, injections) are indicated for caloric supply and carbohydrate supplementation in case of nutrient deprivation. It is also used in metabolic disorders such as hypoglycemia.
Blood glucose is an obligatory energy source in humans involved in various cellular activities, and it also acts as a signalling molecule for diverse glucose-sensing molecules and proteins. Glucose undergoes oxidation into carbon dioxide, water and yields energy molecules in the process of glycolysis and subsequent citric cycle and oxidative phosphorylation. Glucose is readily converted into fat in the body which can be used as a source of energy as required. Under a similar conversion into storage of energy, glucose is stored in the liver and muscles as glycogen. Glucose stores are mobilized in a regulated manner, depending on the tissues' metabolic demands. Oral glucose tablets or injections serve to increase the supply of glucose and oral glucose administration is more effective in stimulating insulin secretion because it stimulates the incretin hormones from the gut, which promotes insulin secretion.
B - Blood and blood forming organs
B05 - Blood substitutes and perfusion solutions
B05C - Irrigating solutions
B05CX - Other irrigating solutions
B05CX01 - Glucose
V - Various
V04 - Diagnostic agents
V04C - Other diagnostic agents
V04CA - Tests for diabetes
V04CA02 - Glucose
V - Various
V06 - General nutrients
V06D - Other nutrients
V06DC - Carbohydrates
V06DC01 - Glucose
Absorption
Polysaccharides can be broken down into smaller units by pancreatic and intestinal glycosidases or intestinal flora. Sodium-dependent glucose transporter SGLT1 and GLUT2 (SLC2A2) play predominant roles in intestinal transport of glucose into the circulation. SGLT1 is located in the apical membrane of the intestinal wall while GLUT2 is located in the basolateral membrane, but it was proposed that GLUT2 can be recruited into the apical membrane after a high luminal glucose bolus allowing bulk absorption of glucose by facilitated diffusion. Oral preparation of glucose reaches the peak concentration within 40 minutes and the intravenous infusions display 100% bioavailability.
Route of Elimination
Glucose can be renally excreted.
Volume of Distribution
The mean volume of distribution after intravenous infusion is 10.6L.
Clearance
The mean metabolic clearance rate of glucose (MCR) for the 10 subjects studied at the higher insulin level was 2.27 0.37 ml/kg/min at euglycemia and fell to 1.510.21 ml/kg/ at hyperglycemia. The mean MCR for the six subjects studied at the lower insulin level was 1.91 0.31 ml/kg/min at euglyglycemia.
Glucose can undergo aerobic oxidation in conjunction to the synthesis of energy molecules. Glycolysis is the initial stage of glucose metabolism where one glucose molecule is degraded into 2 molecules of pyruvate via substrate-level phosphorylation. These products are transported to the mitochondria where they are further oxidized into oxygen and carbon dioxide.
The approximate half-life is 14.3 minutes following intravenous infusion. Gut glucose half-life was markedly higher in females (79 2 min) than in males (65 3 min, P < 0.0001) and negatively related to body height (r = -0.481; P < 0.0001).
Glucose supplies most of the energy to all tissues by generating energy molecules ATP and NADH during a series of metabolism reactions called glycolysis. Glycolysis can be divided into 2 main phases where the preparatory phase is initiated by the phosphorylation of glucose by a hexokinase to form glucose 6-phosphate. The addition of the high-energy phosphate group activates glucose for subsequent breakdown in later steps of glycolysis and is the rate-limiting step. Products end up as substrates for following reactions, to ultimately convert C6 glucose molecule into two C3 sugar molecules. These products enter the energy-releasing phase where total of 4ATP and 2NADH molecules are generated per one glucose molecule. The total aerobic metabolism of glucose can produce up to 36 ATP molecules. This energy-producing reactions of glucose is limited to D-glucose as L-glucose cannot be phosphorlyated by hexokinase. Glucose can act as precursors to generate other biomolecules such as vitamin C. It plays a role as a signaling molecule to control glucose and energy homeostasis. Glucose can regulate gene transcription, enzyme activity, hormone secretion, and the activity of glucoregulatory neurons. The types, number and kinetics of glucose transporters expressed depends on the tissues and fine-tunes glucose uptake, metabolism, and signal generation in order to preserve cellular and whole body metabolic integrity.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36319
Submission : 2021-11-29
Status : Active
Type : IV
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-11-23
Pay. Date : 2015-01-05
DMF Number : 11059
Submission : 1994-09-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35737
Submission : 2021-05-14
Status : Active
Type : II
Registrant Name : Iksoo Pharmaceutical Co., Ltd.
Registration Date : 2023-03-03
Registration Number : 20230303-210-J-1456
Manufacturer Name : Shandong Tianli Pharmaceutical Co., Ltd
Manufacturer Address : South of Anshun street and West of Xingyuan road, Gucheng subdistrict office, Shouguang, Shandong, China
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-08-13
Pay. Date : 2013-12-04
DMF Number : 14294
Submission : 1999-06-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27858
Submission : 2013-12-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27874
Submission : 2013-12-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28948
Submission : 2014-12-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30087
Submission : 2015-11-23
Status : Active
Type : II
Certificate Number : CEP 2021-200 - Rev 01
Issue Date : 2024-01-31
Type : Chemical
Substance Number : 177
Status : Valid
Registration Number : 304MF10090
Registrant's Address : The east of Changda Road, Development, District Changle Country, Weifang City, Shandong Province, China
Initial Date of Registration : 2022-06-22
Latest Date of Registration : --
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26449
Submission : 2012-09-07
Status : Inactive
Type : II
Certificate Number : R0-CEP 2020-019 - Rev 00
Issue Date : 2022-01-14
Type : Chemical
Substance Number : 178
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26450
Submission : 2012-09-07
Status : Inactive
Type : II
Certificate Number : CEP 2017-079 - Rev 01
Issue Date : 2024-01-31
Type : Chemical
Substance Number : 177
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36319
Submission : 2021-11-29
Status : Active
Type : IV
GDUFA
DMF Review : Complete
Rev. Date : 2014-08-13
Pay. Date : 2013-12-04
DMF Number : 14294
Submission : 1999-06-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28948
Submission : 2014-12-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27874
Submission : 2013-12-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27858
Submission : 2013-12-23
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-11-23
Pay. Date : 2015-01-05
DMF Number : 11059
Submission : 1994-09-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35737
Submission : 2021-05-14
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30087
Submission : 2015-11-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26449
Submission : 2012-09-07
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26450
Submission : 2012-09-07
Status : Inactive
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Canada
Brand Name : AVL ELECTROLYTE POWDER
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 41.734G/76G
Packaging :
Approval Date :
Application Number : 2384248
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : AVL ELECTROLYTE POWDER HE
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 149.04G/185G
Packaging : 185G/2/5/10KG
Approval Date :
Application Number : 2408309
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : PRISMASOL 4
Dosage Form : SOLUTION
Dosage Strength : 22G/L
Packaging : 250+4750ML CHAMBER BAG
Approval Date :
Application Number : 2277476
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : OLIMEL 7.6%
Dosage Form : EMULSION
Dosage Strength : 5.97G/L
Packaging :
Approval Date :
Application Number : 2477947
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : PERIOLIMEL 2.5% E
Dosage Form : EMULSION
Dosage Strength : 1.99G/L
Packaging : 1000/1500/2000/2500ML
Approval Date :
Application Number : 2352494
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : OLIMEL 5.7% E
Dosage Form : EMULSION
Dosage Strength : 4.48G/L
Packaging : 1000/1500/2000/2500ML
Approval Date :
Application Number : 2352532
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : OLIMEL 5.7%
Dosage Form : EMULSION
Dosage Strength : 4.48G/L
Packaging : 1000/1500/2000/2500ML
Approval Date :
Application Number : 2352540
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : OLIMEL 7.6% E
Dosage Form : EMULSION
Dosage Strength : 5.97G/L
Packaging : 650/1000/1500/2000ML
Approval Date :
Application Number : 2477955
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : ESSEPNA
Dosage Form : SOLUTION
Dosage Strength : 0.66G/100ML
Packaging :
Approval Date :
Application Number : 2510324
Regulatory Info :
Registration Country : Canada
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Glucose manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Glucose, including repackagers and relabelers. The FDA regulates Glucose manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Glucose API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Glucose manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Glucose supplier is an individual or a company that provides Glucose active pharmaceutical ingredient (API) or Glucose finished formulations upon request. The Glucose suppliers may include Glucose API manufacturers, exporters, distributors and traders.
click here to find a list of Glucose suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Glucose DMF (Drug Master File) is a document detailing the whole manufacturing process of Glucose active pharmaceutical ingredient (API) in detail. Different forms of Glucose DMFs exist exist since differing nations have different regulations, such as Glucose USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Glucose DMF submitted to regulatory agencies in the US is known as a USDMF. Glucose USDMF includes data on Glucose's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Glucose USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Glucose suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Glucose Drug Master File in Japan (Glucose JDMF) empowers Glucose API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Glucose JDMF during the approval evaluation for pharmaceutical products. At the time of Glucose JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Glucose suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Glucose Drug Master File in Korea (Glucose KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Glucose. The MFDS reviews the Glucose KDMF as part of the drug registration process and uses the information provided in the Glucose KDMF to evaluate the safety and efficacy of the drug.
After submitting a Glucose KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Glucose API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Glucose suppliers with KDMF on PharmaCompass.
A Glucose CEP of the European Pharmacopoeia monograph is often referred to as a Glucose Certificate of Suitability (COS). The purpose of a Glucose CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Glucose EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Glucose to their clients by showing that a Glucose CEP has been issued for it. The manufacturer submits a Glucose CEP (COS) as part of the market authorization procedure, and it takes on the role of a Glucose CEP holder for the record. Additionally, the data presented in the Glucose CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Glucose DMF.
A Glucose CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Glucose CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Glucose suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Glucose as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Glucose API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Glucose as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Glucose and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Glucose NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Glucose suppliers with NDC on PharmaCompass.
Glucose Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Glucose GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Glucose GMP manufacturer or Glucose GMP API supplier for your needs.
A Glucose CoA (Certificate of Analysis) is a formal document that attests to Glucose's compliance with Glucose specifications and serves as a tool for batch-level quality control.
Glucose CoA mostly includes findings from lab analyses of a specific batch. For each Glucose CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Glucose may be tested according to a variety of international standards, such as European Pharmacopoeia (Glucose EP), Glucose JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Glucose USP).
LOOKING FOR A SUPPLIER?